NDA 214907 · On Target Labs
Cytalux
Pafolacianine Sodium · Intravenous
NovelPriority reviewOrphanCDER novel approval, Nov 29, 2021: To help identify ovarian cancer lesions
Last checked: Nov 19, 2026Latest source record: Dec 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Nov 29, 2021
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
3 Phase 3, 6 recruiting
FAERS reports
63
13 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 1, 2026.
1. INDICATIONS AND USAGE CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. CYTALUX is an optical imaging agent indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. ( 1 )
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 2022 Supplement 2 · Efficacy · priority review LabelLetter
- Nov 29, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- CYTALUX · PAFOLACIANINE SODIUM EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pafolacianine" as an intervention, any sponsor and status, largest first.
University of PennsylvaniaAcademic, hospital or other
NCT02602119 · 262 participants · Start May 2015 · Primary completion May 2022
Drug: OTL38 · For: Neoplasms
Sites: Philadelphia, Pennsylvania
- OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerPivotal-lookingCompleted
On Target Laboratories, LLCIndustry
NCT03180307 · 140 participants · Start Jan 26, 2018 · Primary completion Apr 16, 2020
Drug: OTL38 · For: Ovarian Cancer
Sites: Phoenix, Arizona; Tucson, Arizona; Duarte, California · 11 sites in all
- ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor TargetingPivotal-lookingCompleted
On Target Laboratories, LLCIndustry
NCT04241315 · 112 participants · Start Mar 26, 2020 · Primary completion Oct 7, 2021
Drug: OTL38 for Injection · For: Lung Neoplasms; Lung Cancer
Sites: Stamford, Connecticut; Iowa City, Iowa; Boston, Massachusetts · 12 sites in all
- CYTALUX Dose Extension StudyNot yet recruiting
On Target Laboratories, LLCIndustry
NCT07469202 · 106 participants (planned) · Start Nov 15, 2026 · Primary completion May 28, 2027
Drug: CYTALUX (pafolacianine) injection · For: Cancer in the Lung; Ovarian Cancer
On Target Laboratories, LLCIndustry
NCT02872701 · 100 participants · Start May 4, 2017 · Primary completion Oct 31, 2018
Drug: OTL38 for Injection · For: Lung Neoplasms; Lung Cancer
Sites: Boston, Massachusetts; Cleveland, Ohio; Philadelphia, Pennsylvania · 6 sites in all
John WatersAcademic, hospital or other
NCT07039526 · 50 participants (planned) · Start Aug 19, 2025 · Primary completion Dec 2027
Drug: CYTALUX™ (pafolacianine) injection preoperatively · For: Esophageal Cancer; Gastrointestinal Cancers; Gynecologic Cancers
Sites: Dallas, Texas
- Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian CancerCompleted
On Target Laboratories, LLCIndustry
NCT02317705 · 48 participants · Start Dec 2014 · Primary completion Nov 2015
Drug: OTL38 · For: Ovarian Cancer
Sites: Orange, California; Tampa, Florida; Rochester, Minnesota · 4 sites in all
University of PennsylvaniaAcademic, hospital or other
NCT02629549 · 33 participants · Start Oct 2015 · Primary completion Aug 3, 2018
Drug: OTL38 · For: Neoplasms; Pituitary Neoplasms
Sites: Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea35
- vomiting20
- pruritus7
- dyspnoea6
- chest discomfort5
- drug effect less than expected4
- flushing4
- wheezing4
- false positive investigation result3
- hyperhidrosis3
- abdominal pain2
- chest pain2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 24 |
| 2025 | 19 |
| 2026 | 18 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Tanyi JL, Randall LM, Chambers SK, et al. · J Clin Oncol 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Pafolacianine for intraoperative molecular imaging of cancer in the lung: The ELUCIDATE trial.
Sarkaria IS, Martin LW, Rice DC, et al. · J Thorac Cardiovasc Surg 2023 · Randomized Controlled Trial
- Intraoperative Molecular Imaging With Pafolacianine in Resection of Occult Pulmonary Malignancy in the ELUCIDATE Trial.
Rice D, Singhal S, Niemeyer E, et al. · Ann Thorac Surg 2025 · Clinical Trial, Phase III, Research Support, N.I.H., Extramural
- Enhancing surgical precision in ovarian cancer with FRα-fluorescence-guided surgery.
Ferrari FA, Ceccaroni M, Scambia G, et al. · Eur J Surg Oncol 2025 · Systematic Review
- Application of fluorescent tracers in ovarian cancer surgical navigation: a systematic review and meta-analysis.
Luo T, Xia Z, Guo Y, et al. · World J Surg Oncol 2025 · Systematic Review, Meta-Analysis
Sponsor: On Target Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.